Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Neuralstem, Inc. (NYSE Amex: CUR) announced it has signed a Memorandum of Understanding with BaYi Brain Hospital in Beijing, China.

21 Apr 2011

Alnylam, Precision NanoSystems enter collaboration for discovery of novel small lipid nanoparticles

Precision NanoSystems, Inc. and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the two companies have formed an exclusive collaboration focused on the discovery and development of novel lipid nanoparticles, known as small lipid nanoparticles ("sLNPs"), using microfluidics technology.

From Precision NanoSystems Inc. 20 Apr 2011

NIST's new reference can aid in Huntington's disease diagnosis

A new Standard Reference Material from the National Institute of Standards and Technology will help clinical genetics labs accurately diagnose Huntington's disease, an inherited degenerative brain disorder that usually begins between ages 35 and 50 and progressively leads to physical impairment, dementia and death.

15 Apr 2011

Insight into neurodegenerative diseases

For years, researchers in genome stability have observed that several neurodegenerative diseases-including Huntington's disease-are associated with cell-killing proteins that are created during expansion of a CAG/CTG trinucleotide repeat.

12 Apr 2011

Alnylam to extend RNAi therapeutics research collaboration with AlCana and UBC

AlCana Technologies, Inc., The University of British Columbia, and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Alnylam has elected to extend the companies' RNAi therapeutics research collaboration for a third year.

7 Apr 2011

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

Neuralstem, Inc. announced that the Phase I safety trial of its human spinal cord stem cells in amyotrophic lateral sclerosis is the subject of three presentations at the American Academy of Neurology Annual Meeting, April 9-16th, in Honolulu, HI.

7 Apr 2011

Alnylam defends against Tekmira complaint, files answer and counterclaim

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, has filed an answer and counterclaim to a complaint filed by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court.

7 Apr 2011

New insight into Huntington's disease

Huntington's disease has long been linked to jerky movements. Now, researchers in Lund, Sweden, have shown that the metabolism can also be seriously affected by the hereditary disease. The new laboratory findings provide hope of entirely new treatment methods.

7 Apr 2011

Huntingtin protein is responsible for metabolic imbalances in hypothalamus

In Huntington's disease, the mutant protein known as huntingtin leads to the degeneration of a part of the brain known as the basal ganglia, causing the motor disturbances that represent one of the most defining features of the fatal disease.

6 Apr 2011

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has completed enrollment in its ALN-VSP Phase I multi-center, multinational, open label, dose escalation clinical trial.

1 Apr 2011

Study identifies unique adult animal stem cells that can turn into neurons

A group of scientists at Marshall University is conducting research that may someday lead to new treatments for repair of the central nervous system.

25 Mar 2011

Xenon founder receives Canada Wightman Award for leadership in medical science

Dr. Michael Hayden, a Xenon founder and Chief Scientific Officer, has received the Canada Gairdner Wightman Award for leadership in medical science in Canada.

23 Mar 2011

Cortex reports net loss of $0.01 per share for quarter ended December 31, 2010

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of $984,000, or $0.01 per share for the quarter ended December 31, 2010 compared with a net loss of $1,599,000, or $0.02 per share for the corresponding prior year period.

18 Mar 2011

Study reveals new mechanism underlying reproduction in plants

A team of researchers at the Instituto Gulbenkian de Ci-ncia (IGC), Portugal, discovered that pollen, the organ that contains the plant male gametes, communicate with the pistil, their female counterpart, using a mechanism commonly observed in the nervous system of animals.

18 Mar 2011

Alnylam to defend against Tekmira complaint

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is reporting the filing of a complaint by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court. The complaint alleges misappropriation and misuse of information, amongst other allegations.

18 Mar 2011

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Neurologix, Inc., announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease were published in an online-first edition of The Lancet Neurology.

17 Mar 2011

Protein folding may aid in developing new therapies for brain diseases

Misfold an origami swan and the worst that happens is you wind up with an ugly paper duckling. Misfold one of the vital proteins in your body - each of which must be folded in a particular way to perform its function - and the result can be a debilitating neurodegenerative disease such as Alzheimer's or Huntington's.

16 Mar 2011

Global settlement agreement reached in Tuschl patents litigation

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the signing of a global settlement agreement among Alnylam, Max Planck Society ("Max Planck"), the Whitehead Institute for Biomedical Research ("Whitehead") and the University of Massachusetts ("UMass") resolving their ongoing litigation regarding the Tuschl patents.

16 Mar 2011

Study identifies potential therapeutic target for neurodegenerative disorders

Cell biologists pondering the death of neurons - brain cells - said today that by eliminating one ingredient from the cellular machinery, they prolonged the life of neurons stressed by a pesticide chemical. The finding identifies a potential therapeutic target to slow changes that lead to neurodegenerative disorders such as Parkinson's and Alzheimer's diseases.

14 Mar 2011

New discovery: GPCR family of proteins can recognize and respond to wide array of signals

Scientists from The Scripps Research Institute have determined a new structure from a medically important superfamily of proteins. The structure should help instruct the design of a new kind of therapeutics for conditions ranging from Parkinson's disease to inflammation.

11 Mar 2011